相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NF449 Is a Novel Inhibitor of Fibroblast Growth Factor Receptor 3 (FGFR3) Signaling Active in Chondrocytes and Multiple Myeloma Cells
Pavel Krejci et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs
V. Ramakrishnan et al.
ONCOGENE (2010)
Stat3 Activates the Receptor Tyrosine Kinase Like Orphan Receptor-1 Gene in Chronic Lymphocytic Leukemia Cells
Ping Li et al.
PLOS ONE (2010)
The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
Michael Hedvat et al.
CANCER CELL (2009)
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo
Renate Burger et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
Indirubin derivatives inhibit malignant lymphoid cell proliferation
Amel Chebel et al.
LEUKEMIA & LYMPHOMA (2009)
Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3
Erik A. Nelson et al.
BLOOD (2008)
Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature
Andreas A. Argyriou et al.
BLOOD (2008)
The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance
Mark B. Meads et al.
CLINICAL CANCER RESEARCH (2008)
Bortezomib in the front-line treatment of multiple myeloma
Paul G. Richardson et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2008)
Individualizing treatment of patients with myeloma in the era of novel agents
Jesus San-Miguel et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
New drugs in multiple myeloma: mechanisms of action and phase I/II clinical findings
Enrique M. Ocio et al.
LANCET ONCOLOGY (2008)
Thalidomide and lenalidomide: Mechanism-based potential drug combinations
Sonia Vallet et al.
LEUKEMIA & LYMPHOMA (2008)
Analysis of STAT1 Activation by Six FGFR3 Mutants Associated with Skeletal Dysplasia Undermines Dominant Role of STAT1 in FGFR3 Signaling in Cartilage
Pavel Krejci et al.
PLOS ONE (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor
Akihiro Muto et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Targeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach
Rafael Fonseca et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Pyridone 6, a pan-janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells
Laura Pedranzini et al.
CANCER RESEARCH (2006)
Signalling and survival pathways in multiple myeloma
Kurt Bommert et al.
EUROPEAN JOURNAL OF CANCER (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells
M Amit-Vazina et al.
BRITISH JOURNAL OF CANCER (2005)
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
S Wuillème-Toumi et al.
LEUKEMIA (2005)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
IL-6 plays a unique role in initiating c-Maf expression during early stage of CD4 T cell activation
Y Yang et al.
JOURNAL OF IMMUNOLOGY (2005)
siRNA target site secondary structure predictions using local stable substructures
BSE Heale et al.
NUCLEIC ACIDS RESEARCH (2005)
Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma
EM Hurt et al.
CANCER CELL (2004)
Rapid assessment of anti-HIV siRNA efficacy using PCR-derived pol III shRNA cassettes
LJ Scherer et al.
MOLECULAR THERAPY (2004)
The protein tyrosine phosphatase CD45 is required for interleukin 6 signaling in U266 myeloma cells
Q Zhou et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2004)
Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines
Y Nefedova et al.
BLOOD (2004)
Curcurnin (diferuloylmethane) inhibits constitutive and IL-6-inducible STAT3 phosphorylation in human multiple myeloma cells
AC Bharti et al.
JOURNAL OF IMMUNOLOGY (2003)
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
PC Heinrich et al.
BIOCHEMICAL JOURNAL (2003)
Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms
Y Nefedova et al.
LEUKEMIA (2003)
Clinical and biologic implications of recurrent genomic aberrations in myeloma
R Fonseca et al.
BLOOD (2003)
A major role for Mcl-1 antiapoptotic protein in the IL-6-induced survival of human myeloma cells
M Jourdan et al.
ONCOGENE (2003)
IL-6-independent expression of Mcl-1 in human multiple myeloma
B Zhang et al.
ONCOGENE (2003)
In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway
M Chatterjee et al.
BLOOD (2002)
Proliferation of IL-6-independent multiple myelorna does not require the activity of extracellular signal-regulated kinases (ERK1/2)
B Zhang et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2002)
Growth mechanism of human myeloma cells by interleukin-6
MM Kawano et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2002)
Myeloid cell factor-1 is a critical survival factor for multiple myeloma
B Zhang et al.
BLOOD (2002)
Deregulated FGFR3 mutants in multiple myeloma cell lines with t(4;14): comparative analysis of Y373C, K650E and the novel G384D mutations
D Ronchetti et al.
ONCOGENE (2001)
Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma
M Chesi et al.
BLOOD (2001)
JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells
J De Vos et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
Diverse karyotypic abnormalities of the c-myc locus associated with c-myc dysregulation and tumor progression in multiple myeloma
YP Shou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
